Biocon Q1 profit rises 71 per cent, revenue up 23 per cent

 Its core EBITDA grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22.

Published: 27th July 2022 10:49 PM  |   Last Updated: 27th July 2022 10:49 PM   |  A+A-

revenue growth, earning estimate

Image for representational purpose only. (File | Photo)

Express News Service

BENGALURU: Biopharmaceuticals company Biocon on Wednesday posted a 71 per cent increase in consolidated net profit at Rs 144 crore for the quarter ended June 2022, compared to Rs 84 crore in the same quarter last year.

The company's consolidated revenue was up 23 per cent y-o-y at Rs 2,217 crore compared to Rs 1,808 crore in the year-ago period. Biocon's EBITDA Margin stood at 22 per cent, as against 24 per cent in Q1FY22.

“We have had a strong start to the year. At a consolidated level, y-o-y revenues grew 23 per cent backed by robust growth in both Biosimilars (29 per cent) and Generics (19 per cent)," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics. Its core EBITDA grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22. 

"Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains," she said.

The company's R&D investments increased significantly by Rs 87 crore in the first quarter. "All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the Covid-19 pandemic," Shaw added.

Biocon Biologics reported a y-o-y growth of 29 per cent for Q1FY23 with revenues at Rs 977 crore. "The strong performance was driven by sales of Glargine in the US, and key biosimilars in emerging markets. Initiation of global clinical trials for two monoclonal antibodies and advancement of our other pipeline assets led to a 120 per cent increase in our R&D investments this quarter," said Arun Chandavarkar, Managing Director, Biocon Biologics.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp